Figure 1.

Survival analysis of SFT treated with pazopanib. Progression-free survival (PFS) and overall survival (OS), according to Choi criteria, of SFT patients with high NLR (>3.78) vs. low NLR (a), high PLR (>242) vs. low PLR (b), and high RDW (>1.03) vs. low (c). NLR, PLR, and RDW were measured before pazopanib treatment. The optimal cut-off point to categorise patients between high and low levels of each inflammatory index was calculated by the maxstat package. Significance between groups was defined at p-values < 0.05.